- Title
- Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6)
- Creators
- Ursula Matulonis - Dana-Farber Cancer InstituteJørn Herrstedt - Zealand University HospitalAmit Oza - Princess Margaret Cancer CentreSven Mahner - LMU KlinikumAndres Redondo - Hospital Universitario La PazDominique BertonJonathan Berek - Stanford UniversityCharlotte Haslund - Aalborg University HospitalFrederik Marmé - Heidelberg UniversityAntonio González-Martín - Clinica Universidad de NavarraStéphanie BecourtAnna Tinker - University of British ColumbiaJonathan Ledermann - CRUK Lung Cancer Centre of ExcellenceBenedict Benigno - Ovarian Cancer InstituteGabriel Lindahl - Linköping University HospitalNicoletta Colombo - European Institute of OncologyIzabela MalinowskaWenlei LiuMichael Schmitz - Amt für Gemeinden und RaumordnungBradley Monk - Creighton UniversityMansoor Mirza - Rigshospitalet
- Publication Details
- Gynecologic oncology, Vol.176, pp.S31-S32
- Identifiers
- 991006041369302656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6)
Gynecologic oncology, Vol.176, pp.S31-S32
09/2023
Metrics
6 Record Views